October 29, 2020

The Niche

Knoepfler lab stem cell blog

Predictions

3 min read

In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based therapy for spinal cord injury. Status: Correct, trial looking encouraging. Upbeat news from ViaCyte on stem cell-based therapy trial for diabetes. Status: Correct, raising $10M and things looking promising. More positive news …Read More

3 min read

Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions. You can see below links to these predictions for past years, which sometimes seems rather far removed from today and in other cases strike me as strangely apropos of …Read More

3 min read

Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, which looks to be a dramatic year in the field of stem cells and regenerative medicine. The Score Card on 2016 Predictions Another stem cell biotech acquisition by pharma …Read More

2 min read

What will the new year have in store for stem cells? 2016 promises to have many striking stem cell developments. Below are my top 20 stem cell predictions for what is to come this year in no particular order. Share your stem cell tea leaves in the comments please. Another stem cell biotech acquisition by pharma (recall Ocata (almost now finally sold) & CDI in 2015). Charging patients for clinical trial participation, particularly in Japan due to the new policy and here in the US …Read More